Compare Ascendis Pharma A/S (ASND) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.18. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | VCIT | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Fixed Income |
52-Week High | $277.18 | $84.82 |
52-Week Low | $189.74 | $81.07 |
Enterprise Value | $17.04B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
